Contract development and manufacturing organisation (CDMO), Provepharm Life Solutions, announced the completion of an expansion to its facilities in Marseille, France, with the building of an active pharmaceutical ingredients (APIs) production plant.
With a €9m ($9.9m) investment, the company built a 500-square-meter pilot plant within its 3,000-square-meters site, aiming to internally cover its supply needs for APIs.
According to the company, the APIs produced at the site will also be ‘transferable under license’ to all of the group’s industrial partners.
The company expects current good manufacturing practice (cGMP) inspections at the site by the French Agence Nationale de Sécurité du Médicament, as well as by the US Food and Drug Administration.
Provepharm also stated that the expansion saw the recruitment of additional employees to be based on the site, which will begin operations in 2020.
Initiating operations at the newly-established plant is set to enable Provepharm to file applications for marketing authorizations of its products in several markets across the globe, the company stated.
Michel Féraud, Provepharm’s CEO said that the expansion is in line with the company’s “goal to fully control the production chain” in order to ensure patients’ access to medicines.
